|
10001
|
Spikevax
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
RNA based vaccine
|
Approved
|
Moderna Inc.
|
2020
|
USA
|
18 years and above
|
2 doses 28 days apart
|
Intramuscular
|
NA
|
Spike protein of SARS-CoV-2 virus
|
mRNA based vaccine
|
US FDA
|
NA
|
USA, Canada, UK, Netherlands, Denmark, Germany, Switzerland
|
mRNA-1273, CX-024414, COVID-19 mRNA Vaccine Moderna, TAK-919, Moderna COVID‑19 Vaccine, COVID‑19 Vaccine Moderna, COVID-19 Vaccine Moderna Intramuscular Injection, Elasomeran
|
NA
|
NCT04969250
|
https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/spikevax-and-moderna-covid-19-vaccine
|
NA
|
|
10002
|
CoronaVac
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Sinovac Biotech Ltd.
|
2021
|
China
|
18 - 59 years
|
2 doses 28 days apart
|
Intramuscular
|
NA
|
Antigenic strain of H1N1, H3N2, BV and BY
|
NA
|
NA
|
NA
|
NA
|
PiCoVacc, Inactivated SARS-CoV-2 vaccine (Vero cell)
|
NA
|
NCT04801888
|
https://clinicaltrials.gov/show/NCT04801888
|
https://cdn.who.int/media/docs/default-source/immunization/sage/2021/april/4_sage29apr2021_sinovac.pdf
|
|
10003
|
Inactivated SARS-CoV-2 vaccine (Vero cell)
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Hubei Provincial Center for Disease Control and Prevention
|
2020
|
China
|
NA
|
NA
|
Intramuscular
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
http://www.chictr.org.cn/showproj.aspx?proj=126385
|
NA
|
|
10004
|
Inactivated SARS-CoV-2 vaccine (Vero cell)
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Shanghai Municipal Center for Disease Control and Prevention
|
2021
|
China
|
NA
|
NA
|
Intramuscular
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
http://www.chictr.org.cn/showproj.aspx?proj=126277
|
NA
|
|
10005
|
KconecaVac
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Shenzhen Kangtai Biological Products Co. Ltd
|
2021
|
China
|
18 years and above
|
2 doses 28 days apart
|
Intramuscular
|
NA
|
NA
|
NA
|
China FDA
|
NA
|
NA
|
NA
|
NA
|
NCT04852705
|
https://clinicaltrials.gov/show/NCT04852705
|
https://www.reuters.com/article/us-health-coronavirus-vaccine-kangtai/kangtai-biologicals-covid-19-vaccine-gets-emergency-use-approval-in-china-idUSKBN2CV1F6
|
|
10006
|
Inactivated SARS-CoV-2 vaccine (Vero cell)
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Shanghai Oriental Hospital
|
2021
|
China
|
NA
|
NA
|
Intramuscular
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
http://www.chictr.org.cn/showproj.aspx?proj=122756
|
NA
|
|
10007
|
Abdala
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Protein subunit
|
Approved
|
Center for Genetic Engineering and Biotechnology
|
2021
|
Cuba
|
19 - 80 years
|
NA
|
Intramuscular
|
Aluminum (aluminium hydroxide)
|
NA
|
NA
|
Cuba Drug Regulator
|
NA
|
Cuba, Venezuela
|
CIGB-66
|
NA
|
NA
|
https://rpcec.sld.cu/en/trials/RPCEC00000363-En
|
https://rpcec.sld.cu/en/trials/RPCEC00000359-En
|
|
10008
|
PiCoVacc
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Approved
|
Sinovac Biotech Ltd.
|
2020
|
China
|
18 - 59 years
|
2 doses 14 or 28 days apart
|
Intramuscular
|
Aluminum (alum)
|
NA
|
NA
|
WHO
|
NA
|
Brazil, Indonesia, Turkey
|
CoronaVac
|
32328406
|
NA
|
https://pubmed.ncbi.nlm.nih.gov/32328406/
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7202686/
|
|
10009
|
Sinopharm Vaccine (Vero cell inactivated)
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Approved
|
Sinopharm
|
2020
|
China
|
NA
|
2 doses 14 or 21 days apart
|
Intramuscular
|
Aluminum (alum)
|
NA
|
NA
|
WHO
|
NA
|
Jordan, Bahrain, Morocco, UAE
|
NA
|
32328406
|
NA
|
https://pubmed.ncbi.nlm.nih.gov/32328406/
|
https://covid19.health.gov.mv/wp-content/uploads/2021/10/SINOPHARM-INFORMATION-SHEET_Final-Revised-09th-June.pdf
|
|
10010
|
BBIBP-CorV (Vero cell) (Covilo)
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Approved
|
China National Biotec Group Company Limited
|
2021
|
China
|
18 years and above
|
2 doses 14 or 28 days apart
|
Intramuscular
|
Aluminum
|
NA
|
NA
|
WHO
|
Beijing Institute of Biotechnology
|
UAE, Jordan, Egypt, Bahrain, Argentina
|
BBIBP-CorV, COVILO
|
32328406
|
NA
|
https://pubmed.ncbi.nlm.nih.gov/32328406/
|
https://www.precisionvaccinations.com/vaccines/sinopharm-covid-19-vaccine-bbibp-corv
|
|
10011
|
Zifivax
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Protein subunit
|
Approved
|
Anhui Zhifei Longcom Biologic Pharmacy Co. Ltd.
|
2020
|
China
|
NA
|
2 doses 2 to 3 days apart
|
Intramuscular
|
NA
|
SARS-CoV-2 receptor-binding domain from spike protein
|
NA
|
China FDA
|
Institute of Microbiology of the Chinese Academy of Sciences
|
China, Uzbekistan, Indonesia, Pakistan, Ecuador
|
RBD-Dimer, ZF2001
|
33816047
|
NCT04646590
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/
|
https://clinicaltrials.gov/ct2/show/NCT05091411
|
|
10012
|
SARS-CoV-2 Vaccine (VeroCell)
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Sinopharm, Beijing Institute of Biological Products
|
2020
|
China
|
NA
|
2 doses 21 days apart
|
Intramuscular
|
NA
|
NA
|
NA
|
WHO
|
NA
|
NA
|
NA
|
33816047
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/
|
https://cdn.who.int/media/docs/default-source/immunization/covid-19/16-june-22080-sinopharm-vaccine-explainer-update.pdf?sfvrsn=ad833095_1&download=true
|
|
10013
|
Covishield
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Recombinant viral vector
|
Approved
|
AstraZeneca plc, University of Oxford, Serum Institute of India
|
2020
|
England
|
NA
|
2 doses 28 days apart
|
Intramuscular
|
NA
|
SARS-CoV-2 Spike gene to the replication defective chimpanzee adenovirus ChAdOx1
|
NA
|
US FDA
|
NA
|
UK, USA, Japan, South Africa
|
AZD1222,ChAdOx1 nCoV-19, ChAdOx1-S, COVID-19 Vaccine AstraZeneca, AstraZeneca COVID-19 Vaccine, AZD2816,Vaxzevria
|
32328406
|
NA
|
https://pubmed.ncbi.nlm.nih.gov/32328406/
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8637436/
|
|
10014
|
Covishield
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
RNA based vaccine
|
Approved
|
AstraZeneca plc, University of Oxford, Serum Institute of India
|
2020
|
England
|
NA
|
NA
|
Intramuscular
|
NA
|
NA
|
mRNA based vaccine
|
European Inclusive Vaccines Alliance
|
NA
|
UK, USA, Brazil, South Africa
|
AZD1222,ChAdOx1 nCoV-19, ChAdOx1-S, COVID-19 Vaccine AstraZeneca, AstraZeneca COVID-19 Vaccine, AZD2816,Vaxzevria
|
33324769
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7729279/
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8637436/
|
|
10015
|
Covishield
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Non-replicating viral vector
|
Approved
|
AstraZeneca plc, University of Oxford, Serum Institute of India
|
NA
|
NA
|
NA
|
2 doses 4 weeks apart
|
Intramuscular
|
NA
|
NA
|
NA
|
NA
|
NA
|
Argentina, India, Morocco, Britain, Mexico, El Salvador, Dominican Republic
|
AZD1222,ChAdOx1 nCoV-19, ChAdOx1-S, COVID-19 Vaccine AstraZeneca, AstraZeneca COVID-19 Vaccine, AZD2816,Vaxzevria
|
NA
|
NA
|
https://vk.ovg.ox.ac.uk/vk/covid-19-vaccines
|
https://www.who.int/news-room/feature-stories/detail/the-oxford-astrazeneca-covid-19-vaccine-what-you-need-to-know
|
|
10016
|
Covishield
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Non-replicating viral vector
|
Approved
|
AstraZeneca plc, University of Oxford, Serum Institute of India
|
NA
|
NA
|
NA
|
2 doses 28 days apart
|
Intramuscular
|
NA
|
NA
|
NA
|
US FDA
|
NA
|
NA
|
AZD1222,ChAdOx1 nCoV-19, ChAdOx1-S, COVID-19 Vaccine AstraZeneca, AstraZeneca COVID-19 Vaccine, AZD2816,Vaxzevria
|
33816047
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/
|
NA
|
|
10017
|
Convidecia
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Recombinant viral vector
|
Approved
|
CanSino Biologics Inc.
|
2020
|
China
|
6 - 59 years
|
2 doses
|
Intramuscular
|
NA
|
Spike protein of SARS-CoV-2 virus
|
Viral vector vaccine using a replication-defective form of the human adenovirus Ad5
|
NMPA
|
Jiangsu Province Centers for Disease Control and Prevention, Insitute of Biotechnology, Academy of Military Medical Sciences, PLA of China
|
China, Chile, Hungary, Malaysia, Mexico, Pakistan
|
Ad5-nCoV
|
32328406
|
NCT04916886
|
https://pubmed.ncbi.nlm.nih.gov/32328406/
|
https://extranet.who.int/pqweb/vaccines/convidecia
|
|
10018
|
JCOVDEN
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Recombinant viral vector
|
Approved
|
Johnson & Johnson
|
2021
|
USA
|
18 - 65 years
|
Single dose
|
Intramuscular
|
NA
|
Spike protein of SARS-CoV-2 virus
|
NA
|
US FDA, WHO
|
NA
|
Netherlands, USA, Argentina, Brazil, Chile, Colombia, Mexico, Peru, Philippines, South Africa, Ukraine, Belgium, Colombia, France, Germany, Philippines, Spain, UK, Europe
|
Ad26.COV2.S, JNJ-78436735,Ad26COVS1, VAC31518,COVID-19 Vaccine Janssen,Johnson & Johnson COVID‑19 vaccine
|
32328406
|
NCT04927936
|
https://pubmed.ncbi.nlm.nih.gov/32328406/
|
https://www.ema.europa.eu/en/documents/product-information/jcovden-previously-covid-19-vaccine-janssen-epar-product-information_en.pdf
|
|
10019
|
JCOVDEN
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Non-replicating viral vector
|
Approved
|
Janssen Pharmaceutical
|
NA
|
NA
|
NA
|
2 doses 56 days apart
|
Intramuscular
|
NA
|
NA
|
NA
|
US FDA
|
NA
|
NA
|
Ad26.COV2.S, JNJ-78436735,Ad26COVS1, VAC31518,COVID-19 Vaccine Janssen,Johnson & Johnson COVID‑19 vaccine
|
33816047
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/
|
https://www.fda.gov/media/153439/download
|
|
10020
|
JCOVDEN
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Recombinant viral vector
|
Approved
|
Janssen Pharmaceutical
|
2020
|
Russia
|
NA
|
2 doses 21 days apart
|
Intramuscular
|
NA
|
Heterologous formulation consisting of two human adenovirus vectors, Ad26 and Ad5, both carrying the SARS-CoV-2 spike protein
|
NA
|
US FDA
|
Health Ministry of the Russian Federation
|
NA
|
Ad26.COV2.S, JNJ-78436735,Ad26COVS1, VAC31518,COVID-19 Vaccine Janssen,Johnson & Johnson COVID‑19 vaccine
|
32328406
|
NA
|
https://pubmed.ncbi.nlm.nih.gov/32328406/
|
NA
|
|
10021
|
Gam-COVID-Vac
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Recombinant viral vector
|
Approved
|
Gamaleya Research Institute of Epidemiology and Microbiology
|
NA
|
Russia
|
NA
|
2 doses 3 weeks apart
|
Intramuscular
|
NA
|
NA
|
NA
|
US FDA
|
Health Ministry of the Russian Federation
|
Russia, Bolivia, Argentina, Algeria, Serbia, Belarus
|
Sputnik-V
|
NA
|
NA
|
https://www.precisionvaccinations.com/vaccines/sputnik-v-vaccine
|
NA
|
|
10022
|
Gam-COVID-Vac
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Recombinant viral vector
|
Approved
|
Gamaleya Research Institute of Epidemiology and Microbiology
|
NA
|
Russia
|
NA
|
NA
|
Intramuscular
|
NA
|
NA
|
NA
|
EMA
|
NA
|
NA
|
Sputnik-V
|
33324769
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7729279/
|
NA
|
|
10023
|
Gam-COVID-Vac
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Non-replicating viral vector
|
Approved
|
Gamaleya Research Institute of Epidemiology and Microbiology
|
NA
|
Russia
|
NA
|
2 doses 21 days apart
|
Intramuscular
|
NA
|
rAd26-S, rAd5-S
|
NA
|
US FDA
|
Health Ministry of the Russian Federation
|
NA
|
Sputnik-V
|
33816047
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/
|
NA
|
|
10024
|
Comirnaty
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
RNA based vaccine
|
Approved
|
BioNTech SE, Pfizer Inc.
|
NA
|
Germany
|
18 - 85 years
|
NA
|
Intramuscular
|
NA
|
SARS-CoV-2 spike protein mRNA encapsulated in a lipid nanoparticle
|
NA
|
US FDA
|
NA
|
USA, Argentina, Brazil, Germany, South Africa, Turkey
|
BNT162b2, COVID-19 mRNA vaccine, Tozinameran
|
32328406
|
NA
|
https://pubmed.ncbi.nlm.nih.gov/32328406/
|
https://www.ema.europa.eu/en/documents/product-information/comirnaty-epar-product-information_en.pdf
|
|
10025
|
Comirnaty
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
RNA based vaccine
|
Approved
|
BioNTech SE, Pfizer Inc.
|
2021
|
Germany, USA
|
NA
|
NA
|
Intramuscular
|
NA
|
NA
|
mRNA based vaccine
|
US FDA
|
NA
|
NA
|
BNT162b2, COVID-19 mRNA vaccine
|
33610448
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7881713/
|
NA
|
|
10026
|
Comirnaty
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
RNA based vaccine
|
Approved
|
BioNTech SE, Pfizer Inc.
|
NA
|
USA
|
12 years and above
|
2 doses 3 weeks apart
|
Intramuscular
|
NA
|
Trimerized SARS-CoV-2 receptor-binding domain from spike protein
|
mRNA based vaccine
|
US FDA
|
NA
|
Argentina, Canada, Chile, Costa Rica, Ecuador, Jordan, Kuwait, Mexico, Panama, Singapore, Bahrain, Saudi Arabia, Switzerland, European Union
|
BNT162b2, COVID-19 mRNA vaccine, Tozinameran
|
33826439
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040490//
|
https://www.comirnaty.com/
|
|
10027
|
Spikevax
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
RNA based vaccine
|
Approved
|
Moderna Inc.
|
2020
|
USA
|
NA
|
2 doses
|
Intramuscular
|
NA
|
SARS-CoV-2 spike protein mRNA encapsulated in a lipid nanoparticle
|
NA
|
US FDA
|
NA
|
NA
|
mRNA-1273, CX-024414, COVID-19 mRNA Vaccine Moderna, TAK-919, Moderna COVID‑19 Vaccine, COVID‑19 Vaccine Moderna, COVID-19 Vaccine Moderna Intramuscular Injection, Elasomeran
|
32328406
|
NA
|
https://pubmed.ncbi.nlm.nih.gov/32328406/
|
https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/Moderna.html
|
|
10028
|
Spikevax
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
RNA based vaccine
|
Approved
|
Moderna Inc.
|
NA
|
NA
|
NA
|
2 doses 28 days apart
|
Intramuscular
|
NA
|
NA
|
NA
|
US FDA
|
National Institute of Allergy and Infectious Diseases
|
NA
|
mRNA-1273, CX-024414, COVID-19 mRNA Vaccine Moderna, TAK-919, Moderna COVID‑19 Vaccine, COVID‑19 Vaccine Moderna, COVID-19 Vaccine Moderna Intramuscular Injection, Elasomeran
|
33816047
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/
|
NA
|
|
10029
|
Spikevax
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
RNA based vaccine
|
Approved
|
Moderna Inc.
|
NA
|
NA
|
NA
|
2 doses 4 weeks apart
|
Intramuscular
|
NA
|
NA
|
NA
|
US FDA
|
NA
|
USA, Canada, Israel, European Union
|
mRNA-1273, CX-024414, COVID-19 mRNA Vaccine Moderna, TAK-919, Moderna COVID‑19 Vaccine, COVID‑19 Vaccine Moderna, COVID-19 Vaccine Moderna Intramuscular Injection, Elasomeran
|
33826439
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040490/
|
NA
|
|
10030
|
Covovax (Nuvaxovid)
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Protein subunit
|
Approved
|
Novavax Inc.
|
NA
|
UK
|
NA
|
2 doses
|
Intramuscular
|
Matrix-M
|
Spike protein of SARS-CoV-2 virus
|
NA
|
US FDA
|
NA
|
USA, Mexico
|
TAK-019, SARS-CoV-2 rS, NVX-CoV2373
|
32328406
|
NA
|
https://pubmed.ncbi.nlm.nih.gov/32328406/
|
https://clinicaltrials.gov/ct2/show/NCT05249816
|
|
10031
|
Covaxin
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Bharat Biotech International Limited
|
2021
|
India
|
18 years and above
|
NA
|
Intramuscular
|
NA
|
NA
|
NA
|
DCGI, WHO
|
Indian Council of Medical Research, Iqvia Pty Ltd
|
NA
|
NA
|
NA
|
NCT04641481
|
https://clinicaltrials.gov/ct2/show/NCT04641481
|
https://www.clinicaltrialsarena.com/projects/covaxin-bbv152-for-the-treatment-of-covid-19/
|
|
10032
|
Covifenz
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Virus like particle
|
Approved
|
Medicago Inc
|
2021
|
Canada
|
18 years and above
|
2 doses 21 days apart
|
Intramuscular
|
AS03
|
NA
|
NA
|
Health Canada
|
NA
|
NA
|
CoVLP
|
NA
|
NCT05040789
|
https://clinicaltrials.gov/ct2/show/NCT05040789
|
https://www.precisionvaccinations.com/vaccines/covifenz-covlp-covid-19-vaccine
|
|
10033
|
EpiVacCorona
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Protein subunit
|
Approved
|
FBRI State Research Center of Virology and Biotechnology
|
2020
|
Russia
|
18 years and above
|
2 doses 21 days apart
|
Intramuscular
|
Aluminum (aluminium hydroxide)
|
SARS CoV-2 peptide antigens
|
NA
|
Russian Federation
|
FBRI State Research Center of Virology and Biotechnology
|
NA
|
EpiVacCorona-N, Aurora-CoV
|
33816047
|
NCT04780035
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/
|
https://www.cnbc.com/2020/10/14/russia-approves-second-covid-19-vaccine-after-preliminary-trials-.html
|
|
10034
|
MVC-COV1901
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Protein subunit
|
Approved
|
Medigen Vaccine Biologics, Dynavax
|
2021
|
Taiwan
|
12 years and above
|
2 doses 28 days apart
|
Intramuscular
|
CpG 1018, aluminium hydroxide
|
S-2P protein
|
NA
|
Taiwan FDA
|
National Institute of Allergy and Infectious Diseases
|
Thailand, Taiwan, Paraguay
|
NA
|
33816047
|
NCT05198596
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/
|
https://www.precisionvaccinations.com/vaccines/medigen-covid-19-vaccine
|
|
10035
|
Comirnaty
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
RNA based vaccine
|
Approved
|
BioNTech SE, Pfizer Inc.
|
2020
|
Germany
|
18 - 55 years
|
2 doses 21 days apart
|
Intramuscular
|
NA
|
Trimerized SARS-CoV-2 receptor-binding domain from spike protein
|
mRNA based vaccine
|
US FDA
|
NA
|
Argentina, Brazil, Germany, South Africa, Turkey, USA
|
BNT162b2, COVID-19 mRNA vaccine
|
33402220
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785400/
|
NA
|
|
10036
|
Spikevax
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
RNA based vaccine
|
Approved
|
Moderna Inc.
|
2020
|
USA
|
18 - 55 years
|
2 doses 28 days apart
|
Intramuscular
|
NA
|
Spike protein of SARS-CoV-2 virus
|
mRNA based vaccine
|
US FDA
|
NA
|
NA
|
mRNA-1273, CX-024414, COVID-19 mRNA Vaccine Moderna, TAK-919, Moderna COVID‑19 Vaccine, COVID‑19 Vaccine Moderna, COVID-19 Vaccine Moderna Intramuscular Injection, Elasomeran
|
33402220
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785400/
|
NA
|
|
10037
|
JCOVDEN
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Virus like particle
|
Approved
|
Janssen Pharmaceutical
|
NA
|
NA
|
18 years and above
|
Single dose
|
Intramuscular
|
NA
|
Spike protein of SARS-CoV-2 virus
|
NA
|
US FDA
|
NA
|
NA
|
Ad26.COV2.S, JNJ-78436735,Ad26COVS1, VAC31518,COVID-19 Vaccine Janssen,Johnson & Johnson COVID‑19 vaccine
|
33402220
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785400/
|
NA
|
|
10038
|
Gam-COVID-Vac
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Virus like particle
|
Approved
|
Gamaleya Research Institute of Epidemiology and Microbiology
|
2020
|
Russia
|
18 - 60 years
|
NA
|
Intramuscular
|
NA
|
Spike protein of SARS-CoV-2 virus
|
NA
|
US FDA
|
Health Ministry of the Russian Federation
|
NA
|
Sputnik-V
|
33402220
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785400/
|
NA
|
|
10039
|
Covovax (Nuvaxovid)
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Protein subunit
|
Approved
|
Novavax Inc.
|
2021
|
USA
|
12 years and above
|
2 doses 21 days apart
|
Intramuscular
|
Matrix-M1
|
Spike protein of SARS-CoV-2 virus
|
NA
|
WHO
|
NA
|
USA, Mexico, Puerto Rico, UK
|
NVX-CoV2373
|
33402220
|
NCT04611802
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785400/
|
https://www.drugs.com/history/novavax-covid-19-vaccine.html
|
|
10040
|
EpiVacCorona
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Protein subunit
|
Approved
|
FBRI State Research Center of Virology and Biotechnology
|
2021
|
Russia
|
18 - 60 years
|
2 doses 21 or 28 days apart
|
Intramuscular
|
Aluminum (aluminium hydroxide)
|
SARS-CoV-2 protein
|
NA
|
Russian Federation
|
FBRI State Research Center of Virology and Biotechnology
|
Cambodia, Russia, Turkmenistan
|
EpiVacCorona-N, Aurora-CoV
|
33402220
|
NCT04780035
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785400/
|
https://clinicaltrials.gov/ct2/show/NCT04780035
|
|
10041
|
COVILO (BBIBP-CorV)
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
China National Biotec Group Company Limited
|
2021
|
China
|
3 years and above
|
2 doses 21 days apart
|
Intramuscular
|
Aluminum (aluminium hydroxide)
|
Inactivated SARS-CoV-2 virus
|
Inactivated SARS-CoV-2 vaccine (Vero cell) is prepared by inoculating African green monkey kidney cells (Vero cell) with the SARS-CoV-2 HB02 strain
|
WHO, Caribbean Regulatory System Emergency Use Recommendation
|
Beijing Institute of Biotechnology
|
China, Bahrain, Egypt, Jordan, UAE, Hungary, Pakistan
|
NA
|
33402220
|
NCT04863638
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785400/
|
https://www.carpha.org/Portals/0/Documents/COVID-19%20Vaccine%20Updates/CARPHA%20COVID-19%20Vaccine%20Update%20047%20December%206%202021.pdf
|
|
10042
|
PiCoVacc
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Sinovac Biotech Ltd.
|
2021
|
Brazil
|
18 - 59 years
|
2 doses 28 days apart
|
Intramuscular
|
NA
|
Inactivated SARS-CoV-2 virus
|
NA
|
WHO, Caribbean Regulatory System Emergency Use Recommendation, Africa Regulatory Taskforce Endorsed
|
NA
|
NA
|
CoronaVac
|
33402220
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785400/
|
https://www.who.int/news/item/01-06-2021-who-validates-sinovac-covid-19-vaccine-for-emergency-use-and-issues-interim-policy-recommendations
|
|
10043
|
Comirnaty
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
RNA based vaccine
|
Approved
|
BioNTech SE, Pfizer Inc.
|
2021
|
Germany, USA
|
NA
|
NA
|
Intramuscular
|
NA
|
NA
|
mRNA based vaccine
|
US FDA
|
NA
|
NA
|
BNT162b2, COVID-19 mRNA vaccine
|
NA
|
NA
|
https://extranet.who.int/pqweb/sites/default/files/documents/Status_of_COVID-19_Vaccines_within_WHO_EUL-PQ_evaluation_process-16June2021_Final.pdf
|
https://www.who.int/publications/m/item/comirnaty-covid-19-mrna-vaccine#:~:text=Pfizer%2DBioNTech%20COVID%2D19%20Vaccine%2C%20COMIRNATY%C2%AE%20(Tozinameran),-COVID%2D19%20Vaccine&text=This%20vaccine%20resource%20provides%20key,disease%20(COVID%2D19).
|
|
10044
|
Covishield
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Recombinant viral vector
|
Approved
|
AstraZeneca plc, University of Oxford, Serum Institute of India
|
2020
|
UK
|
NA
|
NA
|
Intramuscular
|
NA
|
NA
|
Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2
|
EMA
|
NA
|
NA
|
AZD1222,ChAdOx1 nCoV-19, ChAdOx1-S, COVID-19 Vaccine AstraZeneca, AstraZeneca COVID-19 Vaccine, AZD2816,Vaxzevria
|
NA
|
NA
|
https://extranet.who.int/pqweb/sites/default/files/documents/Status_of_COVID-19_Vaccines_within_WHO_EUL-PQ_evaluation_process-16June2021_Final.pdf
|
NA
|
|
10045
|
Covishield
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Recombinant viral vector
|
Approved
|
AstraZeneca plc, University of Oxford, Serum Institute of India
|
NA
|
India
|
NA
|
NA
|
Intramuscular
|
NA
|
NA
|
Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2
|
DCGI
|
NA
|
NA
|
AZD1222,ChAdOx1 nCoV-19, ChAdOx1-S, COVID-19 Vaccine AstraZeneca, AstraZeneca COVID-19 Vaccine, AZD2816,Vaxzevria
|
NA
|
NA
|
https://extranet.who.int/pqweb/sites/default/files/documents/Status_of_COVID-19_Vaccines_within_WHO_EUL-PQ_evaluation_process-16June2021_Final.pdf
|
NA
|
|
10046
|
JCOVDEN
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Non-replicating viral vector
|
Approved
|
Janssen Vaccines & Prevention B.V.
|
NA
|
Leiden, Netherlands
|
NA
|
NA
|
Intramuscular
|
NA
|
NA
|
Recombinant replication-incompetent adenovirus type 26 (Ad26) vectored vaccine encoding Spike protein antigen of the SARS-CoV-2
|
EMA
|
NA
|
NA
|
Ad26.COV2.S, JNJ-78436735,Ad26COVS1, VAC31518,COVID-19 Vaccine Janssen,Johnson & Johnson COVID‑19 vaccine
|
NA
|
NA
|
https://extranet.who.int/pqweb/sites/default/files/documents/Status_of_COVID-19_Vaccines_within_WHO_EUL-PQ_evaluation_process-16June2021_Final.pdf
|
NA
|
|
10047
|
Spikevax
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
RNA based vaccine
|
Approved
|
Moderna Inc.
|
2020
|
USA
|
NA
|
NA
|
Intramuscular
|
NA
|
NA
|
mRNA based vaccine
|
EMA
|
NA
|
NA
|
mRNA-1273, CX-024414, COVID-19 mRNA Vaccine Moderna, TAK-919, Moderna COVID‑19 Vaccine, COVID‑19 Vaccine Moderna, COVID-19 Vaccine Moderna Intramuscular Injection, Elasomeran
|
NA
|
NA
|
https://extranet.who.int/pqweb/sites/default/files/documents/Status_of_COVID-19_Vaccines_within_WHO_EUL-PQ_evaluation_process-16June2021_Final.pdf
|
NA
|
|
10048
|
COVILO (BBIBP-CorV)
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Sinopharm, Beijing Institute of Biological Products
|
NA
|
China
|
NA
|
NA
|
Intramuscular
|
NA
|
Inactivated SARS-CoV-2 virus
|
Produced in vero cells
|
NMPA, WHO
|
NA
|
NA
|
Inactivated SARS-CoV-2 vaccine (Vero cell)
|
NA
|
NA
|
https://cdn.who.int/media/docs/default-source/immunization/covid-19/16-june-22080-sinopharm-vaccine-explainer-update.pdf?sfvrsn=ad833095_1&download=true
|
https://cdn.who.int/media/docs/default-source/immunization/covid-19/16-june-22080-sinopharm-vaccine-explainer-update.pdf?sfvrsn=ad833095_1&download=true
|
|
10049
|
CoronaVac
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Sinovac Biotech Ltd.
|
NA
|
China
|
18 years and above
|
NA
|
Intramuscular
|
Aluminum (aluminium hydroxide)
|
Inactivated SARS-CoV-2 virus
|
Vero cells
|
NMPA, WHO
|
NA
|
NA
|
Inactivated SARS-CoV-2 Vaccine (Vero Cell) (lnCoV),CoronaVac
|
NA
|
NA
|
https://extranet.who.int/pqweb/sites/default/files/documents/Status_of_COVID-19_Vaccines_within_WHO_EUL-PQ_evaluation_process-16June2021_Final.pdf
|
https://clinicaltrials.gov/ct2/show/NCT05107557
|
|
10050
|
Covishield
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Recombinant viral vector
|
Approved
|
AstraZeneca plc, University of Oxford, Serum Institute of India
|
NA
|
UK
|
NA
|
NA
|
Intramuscular
|
NA
|
NA
|
Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2
|
Japan MHLW
|
NA
|
NA
|
AZD1222,ChAdOx1 nCoV-19, ChAdOx1-S, COVID-19 Vaccine AstraZeneca, AstraZeneca COVID-19 Vaccine, AZD2816,Vaxzevria
|
NA
|
NA
|
https://extranet.who.int/pqweb/sites/default/files/documents/Status_of_COVID-19_Vaccines_within_WHO_EUL-PQ_evaluation_process-16June2021_Final.pdf
|
https://www.who.int/publications/m/item/chadox1-s-recombinant-covid-19-vaccine
|
|
10051
|
Covishield
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Recombinant viral vector
|
Approved
|
AstraZeneca plc, University of Oxford, Serum Institute of India
|
NA
|
UK
|
NA
|
NA
|
Intramuscular
|
NA
|
NA
|
Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2
|
Australia TGA
|
NA
|
NA
|
AZD1222,ChAdOx1 nCoV-19, ChAdOx1-S, COVID-19 Vaccine AstraZeneca, AstraZeneca COVID-19 Vaccine, AZD2816,Vaxzevria
|
NA
|
NA
|
https://extranet.who.int/pqweb/sites/default/files/documents/Status_of_COVID-19_Vaccines_within_WHO_EUL-PQ_evaluation_process-16June2021_Final.pdf
|
https://www.who.int/publications/m/item/chadox1-s-recombinant-covid-19-vaccine
|
|
10052
|
Covovax (Nuvaxovid)
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Subunit vaccine
|
Approved
|
Novavax Inc.
|
2020
|
USA
|
NA
|
NA
|
Intramuscular
|
NA
|
NA
|
Recombinant nanoparticle prefusion spike protein formulated with Matrix adjuvant
|
EMA, WHO
|
NA
|
NA
|
TAK-019, SARS-CoV-2 rS, NVX-CoV2373
|
NA
|
NA
|
https://extranet.who.int/pqweb/sites/default/files/documents/Status_of_COVID-19_Vaccines_within_WHO_EUL-PQ_evaluation_process-16June2021_Final.pdf
|
https://www.who.int/news-room/feature-stories/detail/the-novavax-vaccine-against-covid-19-what-you-need-to-know
|
|
10053
|
Covaxin
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Bharat Biotech International Limited
|
NA
|
India
|
NA
|
NA
|
Intramuscular
|
NA
|
NA
|
Produced in vero cells
|
DCGI
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://extranet.who.int/pqweb/sites/default/files/documents/Status_of_COVID-19_Vaccines_within_WHO_EUL-PQ_evaluation_process-16June2021_Final.pdf
|
https://www.precisionvaccinations.com/vaccines/covaxin-covid-19-vaccine
|
|
10054
|
EpiVacCorona
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Protein subunit
|
Approved
|
Vector State Research Centre of Viralogy and Biotechnology
|
NA
|
Russia
|
NA
|
NA
|
Intramuscular
|
NA
|
NA
|
NA
|
Russian Federation
|
NA
|
Russia, Cambodia
|
EpiVacCorona-N, Aurora-CoV
|
NA
|
NCT04780035
|
https://www.cnbc.com/2020/10/14/russia-approves-second-covid-19-vaccine-after-preliminary-trials-.html
|
https://www.precisionvaccinations.com/vaccines/epivaccorona-vaccine#:~:text=EpiVacCorona%20(Aurora%2DCoV)%20is,19%20and%20promotes%20immunity%20development.
|
|
10055
|
Zifivax
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Protein subunit
|
Approved
|
Anhui Zhifei Longcom Biologic Pharmacy Co. Ltd.
|
NA
|
China
|
NA
|
NA
|
Intramuscular
|
NA
|
NA
|
Recombinant
|
UAE
|
NA
|
NA
|
Recombinant Novel Coronavirus Vaccine CHO Cell)
|
NA
|
NCT04550351
|
https://clinicaltrials.gov/ct2/show/NCT04550351
|
https://trialsearch.who.int/Trial2.aspx?TrialID=NCT04646590
|
|
10056
|
Pasteur
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Protein subunit
|
Approved
|
BioCubaFarma
|
2021
|
Cuba
|
NA
|
NA
|
Intramuscular
|
NA
|
Spike protein of SARS-CoV-2 virus
|
NA
|
CECMED
|
NA
|
NA
|
FINLAY-FR-2, Pasteurcovac, Pasto Covac, Soberana 02
|
NA
|
NA
|
https://extranet.who.int/pqweb/sites/default/files/documents/Status_of_COVID-19_Vaccines_within_WHO_EUL-PQ_evaluation_process-16June2021_Final.pdf
|
https://rpcec.sld.cu/trials/RPCEC00000354-En
|
|
10057
|
Corbevax
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Subunit vaccine
|
Approved
|
Biological E Limited
|
2021
|
India
|
18 - 65 years
|
2 doses 28 days apart
|
Intramuscular
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
BECOV2A
|
NA
|
NA
|
http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=48329&EncHid=&userName=covid-19%20vaccine
|
NA
|
|
10058
|
TAK-019
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Protein subunit
|
Approved
|
Takeda Pharmaceutical Company Limited
|
2021
|
USA
|
20 years and above
|
2 doses 21 days apart
|
Intramuscular
|
NA
|
NA
|
NA
|
US FDA, Japan MHLW
|
NA
|
Indonesia, Philippines, Japan
|
NA
|
NA
|
NCT05299359
|
https://clinicaltrials.gov/ct2/show/NCT05299359
|
NA
|
|
10059
|
VLA2001
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Valneva
|
2021
|
Austria
|
18 years and above
|
2 doses 28 days apart
|
Intramuscular
|
CpG 1018, aluminium hydroxide
|
NA
|
NA
|
EMA
|
NA
|
NA
|
NA
|
NA
|
NCT04864561
|
https://clinicaltrials.gov/show/NCT04864561
|
https://valneva.com/press-release/valneva-receives-marketing-authorization-in-europe-for-inactivated-whole-virus-covid-19-vaccine-vla2001/#:~:text=VLA2001%20is%20the%20only%20whole,to%2050%20years%20of%20age.
|
|
10060
|
JCOVDEN
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Non-replicating viral vector
|
Approved
|
Janssen Pharmaceutical
|
2020
|
USA
|
18 years and above
|
NA
|
Intramuscular
|
NA
|
NA
|
NA
|
US FDA, WHO, Africa Regulatory Taskforce Endorsed, Caribbean Regulatory System Emergency Use Recommendation
|
NA
|
Argentina, Brazil, Chile, Colombia, Mexico, Peru, Philippines, South Africa, Ukraine, USA
|
Ad26.COV2.S, JNJ-78436735,Ad26COVS1, VAC31518,COVID-19 Vaccine Janssen,Johnson & Johnson COVID‑19 vaccine
|
NA
|
NCT04436276
|
https://clinicaltrials.gov/show/NCT04436276
|
NA
|
|
10061
|
Razi Cov Pars
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Subunit vaccine
|
Approved
|
Razi Vaccine, Serum Research Institute
|
2021
|
Iran
|
18 years and above
|
2 doses 21 days apart
|
Intramuscular
|
NA
|
NA
|
NA
|
Iran FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.irct.ir/trial/58143
|
NA
|
|
10062
|
SpikoGen
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Subunit vaccine
|
Approved
|
Vaxine, CinnaGen
|
2021
|
Iran
|
18 years and above
|
2 doses 21 days apart
|
Intramuscular
|
Advax-SM
|
Spike protein of SARS-CoV-2 virus
|
NA
|
Iran FDA
|
NA
|
NA
|
NA
|
NA
|
NCT05005559
|
https://covid19.trackvaccines.org/vaccines/8/
|
NA
|
|
10063
|
COVIran Barekat
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Shifa Pharmed Industrial Co.
|
2021
|
Iran
|
18 - 75 years
|
2 doses 28 days apart
|
Intramuscular
|
NA
|
NA
|
NA
|
Iran FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://en.irct.ir/trial/54881
|
https://www.rferl.org/a/iran-domestic-covid-vaccine-coviran-barekat/31307467.html
|
|
10064
|
FINLAY-FR-2
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Subunit vaccine
|
Approved
|
Instituto Finlay de Vacunas
|
2021
|
Cuba
|
19 years and above
|
NA
|
Intramuscular
|
NA
|
NA
|
NA
|
CECMED
|
NA
|
Iran, Cuba
|
Soberana 02
|
NA
|
NA
|
https://www.cecmed.cu/noticias/aprueba-cecmed-autorizo-uso-emergencia-vacunas-cubanas-soberana-02-soberana-plus
|
NA
|
|
10065
|
ZyCoV-D
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
DNA based vaccine
|
Approved
|
Zydus Candila Healthcare Limited
|
2021
|
India
|
12 years and above
|
NA
|
Intradermal
|
NA
|
SARS CoV-2 envelope protein
|
NA
|
DCGI
|
NA
|
India
|
NA
|
NA
|
NA
|
https://pib.gov.in/PressReleasePage.aspx?PRID=1747669#:~:text=Zydus%20Cadila%20has%20received%20approval,adults%2012%20years%20and%20above.
|
NA
|
|
10066
|
FAKHRAVAC
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Erciyes University, Organization of Defensive Innovation and Research
|
2021
|
Iran
|
18 - 70 years
|
NA
|
Intramuscular
|
NA
|
SARS-CoV-2
|
NA
|
Iran FDA
|
Organization of Defensive Innovation and Research
|
NA
|
MIVAC, TURKOVAC
|
NA
|
NA
|
https://en.irct.ir/trial/56027
|
https://www.tehrantimes.com/news/466570/Two-homegrown-vaccines-receive-emergency-use-license
|
|
10067
|
KCONVAC
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Shenzhen Kangtai Biological Products Co. Ltd
|
2021
|
China
|
18 years and above
|
2 doses 28 days apart
|
Intramuscular
|
NA
|
NA
|
NA
|
China FDA
|
Beijing Minhai Biotechnology Co.
|
China, Indonesia
|
NA
|
NA
|
NCT05204589
|
https://clinicaltrials.gov/ct2/show/NCT05204589
|
https://www.reuters.com/article/us-health-coronavirus-vaccine-kangtai/kangtai-biologicals-covid-19-vaccine-gets-emergency-use-approval-in-china-idUSKBN2CV1F6
|
|
10068
|
Afluria Quadrivalent
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Seqirus
|
2007
|
Australia
|
6 months - 35 months
|
NA
|
Intramuscular
|
NA
|
NA
|
Egg based
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/flu/prevent/flushot.htm
|
https://www.cdc.gov/flu/professionals/acip/2021-2022/acip-table.htm
|
|
10069
|
Afluria Quadrivalent
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Seqirus
|
2007
|
Australia
|
3 years and above
|
NA
|
Intramuscular
|
NA
|
NA
|
Egg based
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/flu/prevent/flushot.htm
|
https://www.cdc.gov/flu/professionals/acip/2021-2022/acip-table.htm
|
|
10070
|
Afluria Quadrivalent
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Seqirus
|
NA
|
NA
|
6 months - 64 years
|
NA
|
Intramuscular
|
Thimerosal (24.5) Mercury
|
NA
|
Egg based
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/flu/prevent/flushot.htm
|
https://www.cdc.gov/flu/professionals/acip/2021-2022/acip-table.htm
|
|
10071
|
Fluarix Quadrivalent
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
GlaxoSmithKline
|
NA
|
NA
|
6 months and above
|
Single dose
|
Intramuscular
|
NA
|
Hemagglutinin
|
Egg based
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/flu/prevent/flushot.htm
|
https://www.cdc.gov/flu/professionals/acip/2021-2022/acip-table.htm
|
|
10072
|
FluLaval Quadrivalent
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
GlaxoSmithKline
|
NA
|
NA
|
7 months and above
|
Single dose
|
Intramuscular
|
NA
|
Hemagglutinin
|
Egg based
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/flu/prevent/flushot.htm
|
https://www.cdc.gov/flu/professionals/acip/2021-2022/acip-table.htm
|
|
10073
|
Fluzone Quadrivalent
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Sanofi Pasteur
|
NA
|
NA
|
8 months and above
|
Single dose
|
Intramuscular
|
NA
|
Hemagglutinin
|
Egg based
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/flu/prevent/flushot.htm
|
https://www.cdc.gov/flu/professionals/acip/2021-2022/acip-table.htm
|
|
10074
|
Fluzone Quadrivalent
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Sanofi Pasteur
|
NA
|
NA
|
9 months and above
|
NA
|
Intramuscular
|
NA
|
Hemagglutinin
|
Egg based
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/flu/prevent/flushot.htm
|
https://www.cdc.gov/flu/professionals/acip/2021-2022/acip-table.htm
|
|
10075
|
Fluzone Quadrivalent
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Sanofi Pasteur
|
NA
|
NA
|
10 months and above
|
NA
|
Intramuscular
|
Thimerosal (24.5) Mercury
|
Hemagglutinin
|
Egg based
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/flu/prevent/flushot.htm
|
https://www.cdc.gov/flu/professionals/acip/2021-2022/acip-table.htm
|
|
10076
|
Flucelvax Quadrivalent
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Seqirus
|
NA
|
NA
|
4 years and above
|
Single dose
|
Intramuscular
|
NA
|
Hemagglutinin
|
Cell culture based
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/flu/prevent/flushot.htm
|
https://www.cdc.gov/flu/professionals/acip/2021-2022/acip-table.htm
|
|
10077
|
Flucelvax Quadrivalent
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Seqirus
|
NA
|
NA
|
4 years and above
|
NA
|
Intramuscular
|
Thimerosal (24.5) Mercury
|
Hemagglutinin
|
Cell culture based
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/flu/prevent/flushot.htm
|
https://www.cdc.gov/flu/professionals/acip/2021-2022/acip-table.htm
|
|
10078
|
Fluzone High-Dose Quadrivalent
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Sanofi Pasteur
|
NA
|
NA
|
65 years and above
|
Single dose
|
Intramuscular
|
NA
|
Hemagglutinin
|
Egg based
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/flu/prevent/flushot.htm
|
https://www.cdc.gov/flu/professionals/acip/2021-2022/acip-table.htm
|
|
10079
|
Fluad Quadrivalent
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Seqirus
|
NA
|
NA
|
65 years and above
|
Single dose
|
Intramuscular
|
MF59
|
Hemagglutinin
|
Egg based
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/flu/prevent/flushot.htm
|
https://www.cdc.gov/flu/professionals/acip/2021-2022/acip-table.htm
|
|
10080
|
Fluad Trivalent IIV (IIV3)
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Seqirus
|
NA
|
NA
|
65 years and above
|
Single dose
|
Intramuscular
|
MF59
|
Hemagglutinin
|
Egg based
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/flu/prevent/flushot.htm
|
https://www.cdc.gov/flu/professionals/acip/2021-2022/acip-table.htm
|
|
10081
|
Flublok Quadrivalent
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Approved
|
Sanofi Pasteur
|
2013
|
NA
|
18 years and above
|
Single dose
|
Intramuscular
|
NA
|
Hemagglutinin
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/flu/prevent/flushot.htm
|
https://www.cdc.gov/flu/professionals/acip/2021-2022/acip-table.htm
|
|
10082
|
FluMist Quadrivalent
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Approved
|
AstraZeneca plc
|
2003
|
Canada
|
2 - 49 years
|
Single dose
|
Intranasal
|
NA
|
Hemagglutinin
|
Egg based
|
US FDA
|
NA
|
NA
|
Tamiflu, Relenza
|
NA
|
NA
|
https://www.cdc.gov/flu/prevent/flushot.htm
|
https://www.cdc.gov/flu/professionals/acip/2021-2022/acip-table.htm
|
|
10083
|
IL-YANG Quadrivalent Seasonal Influenza Vaccine
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Ilyang pharmaceutical Co. Ltd.
|
2020
|
South Korea
|
3 - 18 years
|
Single dose
|
Intramuscular
|
NA
|
Inactivated Influenza virus
|
NA
|
MFDS
|
NA
|
NA
|
NA
|
NA
|
NCT03445468
|
https://clinicaltrials.gov/ct2/show/NCT03445468?recrs=ade&cond=Influenza%2C+Human&phase=23&draw=2&rank=4
|
https://www.clincosm.com/trial/influenza-il-yang-quadrivalent-vaccine-flu-prefilled-syringe
|
|
10084
|
ERVEBO
|
Ebola
|
Hemorrhagic
|
Zaire ebolavirus
|
negative-sense, single-stranded RNA
|
Live-attenuated
|
Approved
|
Merck & Co. Inc.
|
2019
|
USA
|
18 years and above
|
Single dose
|
Intramuscular
|
NA
|
Zaire Ebola virus glycoprotein
|
NA
|
US FDA, EMA
|
NA
|
NA
|
V920, rVSV-G-ZEBOV-GP, rVSV-ZEBOV
|
NA
|
NA
|
https://www.cdc.gov/vhf/ebola/clinicians/vaccine/index.html
|
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2817%2930313-4/fulltext
|
|
10085
|
Ad26.ZEBOV
|
Ebola
|
Hemorrhagic
|
Zaire ebolavirus
|
negative-sense, single-stranded RNA
|
Recombinant viral vector
|
Approved
|
Janssen Pharmaceutical
|
2020
|
USA
|
1 year and above
|
Single dose of Zabdeno on day 0 followed by 0.5mL dose of Mvabea post 8 week
|
Intramuscular
|
NA
|
Adenovirus type 26 encoding the Zaire ebolavirus, Mayinga variant glycoprotein
|
NA
|
US FDA, EMA
|
NA
|
NA
|
MVA-BN-Filo
|
NA
|
NCT02509494
|
https://clinicaltrials.gov/ct2/show/NCT02509494
|
https://clinicaltrials.gov/ct2/show/NCT05284097
|
|
10086
|
YF-Vax
|
Yellow fever
|
Hemorrhagic
|
Yellow fever virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Approved
|
Sanofi Pasteur
|
NA
|
France
|
9 months and above
|
Single dose
|
Subcutaneous
|
NA
|
17D-204 strain of yellow fever virus
|
Culturing 17D-204 strain of yellow fever virus in living avian leukosis virus-free (ALV-free) chicken embryos
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.fda.gov/media/76015/download
|
https://www.fda.gov/media/76015/download
|
|
10087
|
CYD-TDV Dengvaxia
|
Dengue fever
|
Hemorrhagic
|
Dengue virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Approved
|
Sanofi Pasteur
|
2015
|
France
|
9 - 45 years
|
3 doses 6 months apart
|
Subcutaneous
|
NA
|
Dengue virus serotypes (1, 2, 3 and 4)
|
17D vaccine vector expressing genes of DENV-1, 2, 3, or 4
|
US FDA
|
NA
|
NA
|
NA
|
30684747
|
NCT02747927
|
https://www.sciencedirect.com/science/article/pii/S1201971219300402
|
https://www.fda.gov/media/124379/download
|
|
10088
|
Weisairuiji Biovac-A Mevac-A
|
Hepatitis A
|
Hepatitic
|
Hepatitis A virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Approved
|
Biogenetech Co. Ltd., Zhejiang Pukang Biotechnology Co. Ltd.
|
2010
|
Thailand
|
1.5 years and above
|
Single dose
|
Subcutaneous
|
NA
|
H2 strain of HAV
|
H2-attenuated strain of HAV cultured in human diploid cells.
|
China FDA, US FDA
|
NA
|
NA
|
MEVAC-A
|
24280971
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4130259/
|
https://apps.who.int/iris/bitstream/handle/10665/326501/97892516327-eng.pdf
|
|
10089
|
Weisairuiji Biovac-A Mevac-A
|
Hepatitis A
|
Hepatitic
|
Hepatitis A virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Approved
|
Institute of Medical Biology, Chinese Academy of Medical Sciences
|
NA
|
China
|
NA
|
Single dose
|
Subcutaneous
|
NA
|
H2 strain of HAV
|
NA
|
China FDA, US FDA
|
NA
|
NA
|
NA
|
29661808
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360863/
|
https://www.fda.moph.go.th/sites/drug/Shared%20Documents/Vaccine/U1DR1C1072530000811C-SPC.pdf
|
|
10090
|
HAVAC
|
Hepatitis A
|
Hepatitic
|
Hepatitis A virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Approved
|
Changchun Institute of Biological Products
|
NA
|
China
|
NA
|
Single dose
|
Subcutaneous
|
NA
|
LA-1
|
NA
|
Government of Canada
|
Changchun Changsheng Life Sciences
|
NA
|
NA
|
24280971
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4130259/
|
https://www.canada.ca/en/public-health/services/publications/healthy-living/update-recommended-use-hepatitis-b-vaccine.html
|
|
10091
|
HAVAC
|
Hepatitis A
|
Hepatitic
|
Hepatitis A virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Approved
|
Changchun Institute of Biological Products
|
NA
|
China
|
NA
|
Single dose
|
Subcutaneous
|
NA
|
LA-1
|
NA
|
Government of Canada
|
Changchun Changsheng Life Sciences
|
NA
|
NA
|
29661808
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360863/
|
https://www.canada.ca/en/public-health/services/publications/healthy-living/update-recommended-use-hepatitis-b-vaccine.html
|
|
10092
|
HAVRIX
|
Hepatitis A
|
Hepatitic
|
Hepatitis A virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
GlaxoSmithKline
|
NA
|
Belgium
|
NA
|
P: 720 EU; Adults: 1440 EU; 2 doses 0, 6–12
|
Intramuscular
|
Aluminum (aluminium hydroxide)
|
HM-175
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
29661808
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360863/
|
https://www.fda.gov/files/vaccines%2C%20blood%20%26%20biologics/published/Package-Insert---HAVRIX.pdf
|
|
10093
|
VAQTA
|
Hepatitis A
|
Hepatitic
|
Hepatitis A virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Merck & Co. Inc.
|
NA
|
USA
|
NA
|
P: 25 U; Adults: 50 U; 2 doses 0, 6–18
|
Intramuscular
|
Aluminum (aluminium hydroxide)
|
CR-326
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
29661808
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360863/
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/vaqta
|
|
10094
|
AVAXIM
|
Hepatitis A
|
Hepatitic
|
Hepatitis A virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Sanofi Pasteur
|
NA
|
Lyon, France
|
NA
|
P: 80 U; Adults: 160 U
|
Intramuscular
|
Aluminum (aluminium hydroxide)
|
GBM
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
29661808
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360863/
|
https://www.fda.moph.go.th/sites/drug/Shared%20Documents/Vaccine/U1DR1C1062460010911C-SPC.pdf
|
|
10095
|
Healive
|
Hepatitis A
|
Hepatitic
|
Hepatitis A virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Sinovac Biotech Ltd.
|
NA
|
China
|
NA
|
P: 250 U; Adults: 500 U
|
Intramuscular
|
Aluminum (aluminium hydroxide)
|
TZ-84
|
NA
|
China FDA
|
NA
|
NA
|
NA
|
29661808
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360863/
|
http://www.sinovac.com/news/shownews.php?id=764&lang=en
|
|
10096
|
Weisairuiji Biovac-A Mevac-A
|
Hepatitis A
|
Hepatitic
|
Hepatitis A virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Institute of Medical Biology, Chinese Academy of Medical Sciences
|
NA
|
China
|
NA
|
P: 320 EU; Adults: 640 EU
|
Intramuscular
|
Aluminum (aluminium hydroxide)
|
Lv-8
|
NA
|
China FDA
|
NA
|
NA
|
NA
|
29661808
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360863/
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7482852/
|
|
10097
|
Veraxim
|
Hepatitis A
|
Hepatitic
|
Hepatitis A virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Shanghai Wilson Bioengineering
|
NA
|
China
|
NA
|
P: 800 EU; Adults: 1600 EU
|
Intramuscular
|
Aluminum (aluminium hydroxide)
|
YN-5
|
NA
|
Government of China
|
NA
|
NA
|
NA
|
29661808
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360863/
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360863/
|
|
10098
|
HAVRIX
|
Hepatitis A
|
Hepatitic
|
Hepatitis A virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
GlaxoSmithKline
|
NA
|
Belgium
|
12 months and above
|
Single dose for adult and 2 doses 6 to 12 months apart for infants
|
Intramuscular
|
NA
|
NA
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/hepatitis/hav/havfaq.htm#vaccine
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/havrix
|
|
10099
|
VAQTA
|
Hepatitis A
|
Hepatitic
|
Hepatitis A virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Merck & Co. Inc.
|
NA
|
USA
|
12 months and above
|
2 doses 6 to 18 months apart
|
Intramuscular
|
NA
|
NA
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/hepatitis/hav/havfaq.htm#vaccine
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/vaqta
|
|
10100
|
TWINRIX
|
Hepatitis A, Hepatitis B
|
Hepatitic
|
Hepatitis A, Hepatitis B virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
GlaxoSmithKline
|
NA
|
Rixensart, Belgium
|
18 years and above
|
3 doses at regimen of 0, 1, and 6 months
|
Intramuscular
|
Aluminum
|
Strain HM175, HBsAg
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/hepatitis/hav/havfaq.htm#vaccine
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/twinrix
|
|
10101
|
ENGERIX-B
|
Hepatitis B
|
Hepatitic
|
Hepatitis B virus
|
double stranded DNA
|
DNA based vaccine
|
Approved
|
GlaxoSmithKline
|
NA
|
Rixensart, Belgium
|
All age group
|
3 doses at regimen of 0, 1, and 6 months
|
Intramuscular
|
NA
|
HBsAg
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/hepatitis/hbv/hbvfaq.htm#vaccFAQ
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/engerix-b
|
|
10102
|
RECOMBIVAX HB
|
Hepatitis B
|
Hepatitic
|
Hepatitis B virus
|
double stranded DNA
|
Protein subunit
|
Approved
|
Merck & Co. Inc.
|
NA
|
USA
|
All age group
|
2 doses 6 months apart
|
Intramuscular
|
NA
|
HBsAg
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/hepatitis/hbv/hbvfaq.htm#vaccFAQ
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/recombivax-hb
|
|
10103
|
HEPLISAV-B
|
Hepatitis B
|
Hepatitic
|
Hepatitis B virus
|
double stranded DNA
|
Subunit vaccine
|
Approved
|
Dynavax
|
NA
|
NA
|
18 years and above
|
2 doses 1 month apart
|
Intramuscular
|
CpG
|
HepB
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/hepatitis/hbv/hbvfaq.htm#vaccFAQ
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/heplisav-b
|
|
10104
|
PEDIARIX
|
Hepatitis B, Diphtheria, Tetanus, Acellular pertussis , Poliomyelitis
|
Hepatitic
|
Hepatitis B virus
|
double stranded DNA
|
NA
|
Approved
|
GlaxoSmithKline
|
NA
|
USA
|
6 weeks - 7 years
|
2 doses 6 months apart
|
Intramuscular
|
NA
|
HBsAg
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/hepatitis/hbv/hbvfaq.htm#vaccFAQ
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/pediarix
|
|
10105
|
HBVaxPRO
|
Hepatitis B
|
Hepatitic
|
Hepatitis B virus
|
double stranded DNA
|
Subunit vaccine
|
Approved
|
Sanofi Pasteur
|
NA
|
USA
|
18 years and above
|
NA
|
Intramuscular
|
NA
|
HBsAg
|
NA
|
EMA
|
NA
|
NA
|
NA
|
26208678
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4685678/
|
https://www.ema.europa.eu/en/documents/overview/hbvaxpro-epar-summary-public_en.pdf
|
|
10106
|
Fendrix
|
Hepatitis B
|
Hepatitic
|
Hepatitis B virus
|
double stranded DNA
|
NA
|
Approved
|
GlaxoSmithKline
|
NA
|
Belgium
|
NA
|
NA
|
Intradermal, Intravenous
|
AS043
|
HBsAg
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
26208678
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4685678/
|
https://www.ema.europa.eu/en/medicines/human/EPAR/fendrix
|
|
10107
|
Hecolin (Hepatitis vaccine -239)
|
Hepatitis E
|
Hepatitic
|
Hepatitis E virus
|
double stranded DNA
|
Virus like particle
|
Approved
|
Xiamen Innovax Biotech
|
2011
|
China
|
NA
|
3 doses at regimen of 0, 1, and 6 months
|
Intramuscular
|
NA
|
HEV-1 Chinese strain
|
NA
|
China FDA
|
NA
|
NA
|
NA
|
27610014
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4988308/
|
https://www.precisionvaccinations.com/vaccines/hecolin-hepatitis-e-vaccine
|
|
10108
|
Hecolin (Hepatitis vaccine -239)
|
Hepatitis E
|
Hepatitic
|
Hepatitis E virus
|
double stranded DNA
|
Recombinant viral vector
|
Approved
|
Xiamen Innovax Biotech
|
2011
|
China
|
NA
|
3 doses at regimen of 0, 1, and 6 months
|
Intramuscular
|
Aluminum (aluminium hydroxide)
|
Capsid Protein ORF2
|
NA
|
China FDA
|
NA
|
NA
|
Hecolin
|
29546064
|
NCT01014845
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818934/
|
https://www.precisionvaccinations.com/vaccines/hecolin-hepatitis-e-vaccine
|
|
10109
|
AMBIRIX
|
Hepatitis A, Hepatitis B
|
Hepatitic
|
Hepatitis A, Hepatitis B virus
|
double stranded DNA
|
Inactivated
|
Approved
|
GlaxoSmithKline
|
2002
|
Belgium
|
1 - 15 years
|
2 doses 6 to 12 months apart
|
Intramuscular
|
Aluminum (aluminium hydroxide)
|
Inactivated hepatitis A virus and surface antigen of hepatitis B virus
|
Produced on human diploid (MRC-5) cells
|
EMA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.ema.europa.eu/en/documents/product-information/ambirix-epar-product-information_en.pdf
|
https://www.ema.europa.eu/en/documents/product-information/ambirix-epar-product-information_en.pdf
|
|
10110
|
AMBIRIX
|
Hepatitis A, Hepatitis B
|
Hepatitic
|
Hepatitis A, Hepatitis B virus
|
double stranded DNA
|
Inactivated
|
Approved
|
GlaxoSmithKline
|
2002
|
Belgium
|
2 - 15 years
|
2 doses 6 to 12 months apart
|
Intramuscular
|
Aluminum (aluminum phosphate)
|
Inactivated hepatitis A virus and surface antigen of hepatitis B virus
|
Produced in yeast cells (Saccharomyces cerevisiae) by recombinant DNA technology
|
EMA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.ema.europa.eu/en/documents/product-information/ambirix-epar-product-information_en.pdf
|
https://www.ema.europa.eu/en/documents/product-information/ambirix-epar-product-information_en.pdf
|
|
10111
|
VIVAXIM
|
Hepatitis A, Typhoid
|
Hepatitic
|
Hepatitis A virus, Salmonella typhi
|
double stranded DNA
|
NA
|
Approved
|
Sanofi Pasteur
|
2007
|
France
|
16 years and above
|
Single dose
|
Intramuscular
|
Aluminum (aluminium hydroxide)
|
Salmonella typhi Vi polysaccharide (Ty 2 strain) and formaldehyde inactivated hepatitis A virus antigen (GBM strain)
|
GBM strain cultured on MRC-5 human diploid cells
|
Government of Canada
|
NA
|
NA
|
VIATIM
|
NA
|
NA
|
http://products.sanofi.com.au/vaccines/VIVAXIM_NZ_PI.pdf
|
https://pdf.hres.ca/dpd_pm/00032177.PDF
|
|
10112
|
Imovax Rabies(Pre exposure)
|
Rabies
|
Neurologic
|
Rabies virus
|
negative-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Sanofi Pasteur
|
2005
|
France
|
All age group
|
3 doses on day 0, 7 and 21
|
Intramuscular
|
NA
|
WISTAR Rabies PM/WI38-1503-3M strain
|
Human diploid cell vaccine
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/vaccines/vpd/rabies/hcp/index.html#ref
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/imovax
|
|
10113
|
Imovax Rabies(Post exposure)
|
Rabies
|
Neurologic
|
Rabies virus
|
negative-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Sanofi Pasteur
|
2005
|
France
|
All age group
|
5 doses on day 0, 3, 7, 14 and 28
|
Intramuscular
|
NA
|
WISTAR Rabies PM/WI38-1503-3M strain
|
Human diploid cell vaccine
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/vaccines/vpd/rabies/hcp/index.html#ref
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/imovax
|
|
10114
|
RabAvert
|
Rabies
|
Neurologic
|
Rabies virus
|
negative-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Novartis
|
NA
|
NA
|
All age group
|
4 doses on day 0, 3, 7 and 14
|
Intramuscular
|
NA
|
NA
|
Purified chick embryo cell
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/vaccines/vpd/rabies/hcp/index.html#ref
|
https://www.fda.gov/files/vaccines%2C%20blood%20&%20biologics/published/Package-Insert---RabAvert.pdf
|
|
10115
|
Imogam Rabies-HT
|
Rabies
|
Neurologic
|
Rabies virus
|
negative-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Sanofi Pasteur
|
NA
|
NA
|
All age group
|
4 doses on day 0, 7 and 21 or 28
|
Intramuscular
|
NA
|
NA
|
Rabies Immunoglobin
|
Government of Canada
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/vaccines/vpd/rabies/hcp/index.html#ref
|
https://www.sanofi.ca/dam/jcr:21c480e0-afcd-4a38-bfee-fb9b7a6b21e0/imogam-rabies-pasteurized.pdf
|
|
10116
|
HyperRabTM S/D
|
Rabies
|
Neurologic
|
Rabies virus
|
negative-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Talecris Biotherapeutics Bayer Biological Products
|
NA
|
NA
|
NA
|
NA
|
Intramuscular
|
NA
|
NA
|
Rabies Immunoglobin
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/vaccines/vpd/rabies/hcp/index.html#ref
|
https://www.hyperrab.com/en/hcp
|
|
10117
|
Verorab
|
Rabies
|
Neurologic
|
Rabies virus
|
negative-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Sanofi Pasteur
|
2015
|
France
|
NA
|
5 doses on day 0, 3, 7, 14 and 28
|
Intramuscular
|
NA
|
WISTAR Rabies PM/WI38-1503-3M strain
|
Purified vero cell rabies vaccine
|
DCGI
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/vaccines/vpd/rabies/hcp/index.html#ref
|
https://ncdc.gov.in/WriteReadData/l892s/File557.pdf
|
|
10118
|
Lyssavac N
|
Rabies
|
Neurologic
|
Rabies virus
|
negative-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Zydus Candila Healthcare Limited
|
NA
|
India
|
NA
|
3 doses on day 0, 7 and 21
|
Intramuscular
|
NA
|
NA
|
Purified duck embryo cell
|
WHO
|
Berna Biotech
|
NA
|
NA
|
NA
|
NA
|
https://www.fda.moph.go.th/sites/drug/Summary/1C_278_50_Lyssavac%20N%20Injection.pdf
|
https://www.livemint.com/Companies/XopdfNnBp4Y6189QY3PY2N/Zydus-Cadila-receives-WHO-nod-for-rabies-vaccine.html
|
|
10119
|
Rabipur
|
Rabies
|
Neurologic
|
Rabies virus
|
negative-sense, single-stranded RNA
|
Inactivated
|
Approved
|
GlaxoSmithKline
|
NA
|
NA
|
All age group
|
3 doses on day 0, 7 and 21
|
Intramuscular
|
NA
|
NA
|
Purified chick embryo cell
|
DCGI
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/vaccines/vpd/rabies/hcp/index.html#ref
|
https://www.wbhealth.gov.in/uploaded_files/IDSP/Guideline_Rabies_prophylaxis_PPT_PDF.pdf
|
|
10120
|
Rabivax-S
|
Rabies
|
Neurologic
|
Rabies virus
|
negative-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Ross University School of Veterinary Medicine
|
2019
|
India
|
All age group
|
3 doses on day 0, 7 and 21
|
Intramuscular
|
NA
|
NA
|
Human diploid cell vaccine
|
DCGI
|
Serum Institute of India
|
NA
|
NA
|
NA
|
NCT03741270
|
https://clinicaltrials.gov/ct2/show/NCT03741270
|
http://test.pharmabiz.com/news/serum-institute-launches-rabies-vaccine-rabivax-24382
|
|
10121
|
KAMRAB-003
|
Rabies
|
Neurologic
|
Rabies virus
|
negative-sense, single-stranded RNA
|
Live-attenuated
|
Approved
|
Kamada Ltd.
|
2014
|
USA
|
18 - 75 years
|
5 doses on day 0, 3, 7, 14 and 28
|
Intramuscular
|
NA
|
NA
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NCT02040090
|
https://clinicaltrials.gov/ct2/show/NCT02040090?cond=Rabies+Human&phase=23&draw=2&rank=5
|
https://pdf.hres.ca/dpd_pm/00048173.PDF
|
|
10122
|
Speeda
|
Rabies
|
Neurologic
|
Rabies virus
|
negative-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Beijing Center for Disease Control and Prevention
|
2013
|
China
|
NA
|
3 doses on day 0, 7 and 21
|
Intramuscular
|
NA
|
NA
|
NA
|
Thailand FDA
|
NA
|
NA
|
NA
|
NA
|
NCT01821911
|
https://clinicaltrials.gov/ct2/show/NCT01821911?cond=Rabies+Human&phase=23&draw=2&rank=7
|
https://www.immunize.org/askexperts/experts_rab.asp
|
|
10123
|
SA14-14-2 (IXIARO)
|
Viral encephalitis
|
Neurologic
|
West Nile virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Approved
|
Sanofi Pasteur
|
2013
|
Thailand
|
NA
|
NA
|
Subcutaneous
|
NA
|
SA 14-14-2
|
Cell culture based
|
NA
|
NA
|
NA
|
NA
|
24161909
|
NCT01092507
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4185882/
|
https://www.fda.gov/media/75777/download
|
|
10124
|
ENCEVAC
|
Viral encephalitis
|
Neurologic
|
West Nile virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Research Foundation for Microbial Diseases of Osaka University
|
NA
|
NA
|
NA
|
NA
|
Subcutaneous
|
NA
|
Beijing-1(P1)
|
Cell culture based
|
NA
|
NA
|
NA
|
JEBIK V (BIKEN), KD-287, JEIMMUGEN INJ (Kaketsuken)
|
24161909
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4185882/
|
https://ifli.wisc.edu/wp-content/uploads/sites/528/2019/05/Japanese-Encephalitis.pdf
|
|
10125
|
IXIARO
|
Viral encephalitis
|
Neurologic
|
West Nile virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Valneva
|
NA
|
UK
|
2 months and above
|
2 doses 28 days apart
|
Intramuscular
|
Aluminum (aluminium hydroxide)
|
Beijing-3(P3), SA14-14-2
|
Cell culture based
|
US FDA
|
NA
|
New Zealand, Europe, India, China, US, Japan
|
IC51, JESPECT, JEEV (Intercell AG) in Australia
|
24161909
|
NA
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4185882/
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/ixiaro
|
|
10126
|
IMOJEV
|
Viral encephalitis
|
Neurologic
|
West Nile virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Approved
|
Sanofi Pasteur
|
2017
|
Thailand
|
9 months and above
|
3 doses
|
Subcutaneous
|
NA
|
SA 14-14-2
|
Mouse brain based
|
US FDA
|
NA
|
NA
|
ChimeriVax-JE, JE-CV, THAIJEV (Sanofi-Aventis)
|
24161909
|
NCT01900444
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4185882/
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/japanese-encephalitis-vaccine-inactivated-adsorbed
|
|
10127
|
IPOL
|
Poliomyelitis
|
Neurologic
|
Poliovirus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Sanofi Pasteur
|
NA
|
NA
|
6 months and above
|
2-3 doses depending on volume and age
|
Intramuscular
|
NA
|
P1, P2 and P3
|
Monkey kidney cell
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/ipol-poliovirus-vaccine-inactivated-monkey-kidney-cell
|
NA
|
|
10128
|
KINRIX
|
Poliomyelitis
|
Neurologic
|
Poliovirus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
GlaxoSmithKline
|
2008
|
NA
|
4 - 6 years
|
5 doses
|
Intramuscular
|
NA
|
P1, P2 and P4
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/kinrix
|
NA
|
|
10129
|
PEDIARIX
|
Poliomyelitis
|
Neurologic
|
Poliovirus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
GlaxoSmithKline
|
2002
|
NA
|
6 weeks - 6 years
|
3 doses at regimen of 2, 4, and 6 months of age.
|
Intramuscular
|
NA
|
P1, P2 and P5
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/pediarix
|
NA
|
|
10130
|
Pentacel
|
Poliomyelitis
|
Neurologic
|
Poliovirus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Sanofi Pasteur
|
2008
|
NA
|
6 weeks - 4 years
|
4 doses at regimen of 2, 4, 6 and 15-18 months of age
|
Intramuscular
|
NA
|
P1, P2 and P6
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/pentacel
|
NA
|
|
10131
|
ACAM2000
|
Smallpox
|
Exanthous
|
Variola virus
|
double stranded DNA
|
Live-attenuated
|
Approved
|
Emergent BioSolutions
|
2003
|
USA
|
Below 12 months of age
|
Single dose
|
Percutaneous
|
NA
|
Recombinant vaccinia viruses derived from replication-competent vaccinia strain
|
Lyophilized
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/acam2000
|
NA
|
|
10132
|
JYNNEOS
|
Smallpox
|
Exanthous
|
Variola virus
|
double stranded DNA
|
Live-attenuated
|
Approved
|
Bavarian Nordic
|
NA
|
Denmark
|
18 years and above
|
2 doses 4 weeks apart
|
Subcutaneous
|
NA
|
Vaccinia Virus Ankar
|
NA
|
US FDA
|
NA
|
NA
|
Imvamune, Imvanex, MVA-BN
|
NA
|
NA
|
https://www.fda.gov/vaccines-blood-biologics/jynneos
|
https://www.fda.gov/media/131078/download
|
|
10133
|
Aventis Pasteur Smallpox Vaccine
|
Smallpox
|
Exanthous
|
Variola virus
|
double stranded DNA
|
Live-attenuated
|
Approved
|
National Institute of Allergy and Infectious Diseases
|
2010
|
USA
|
18 - 32 years
|
NA
|
Percutaneous
|
NA
|
NA
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NCT00038987
|
https://www.fda.gov/emergency-preparedness-and-response/mcm-issues/smallpox-preparedness-and-response-updates-fda
|
https://clinicaltrials.gov/ct2/show/NCT00038987
|
|
10134
|
Priorix
|
Measles, Mumps, Rubella, Chickenpox
|
Exanthous
|
Morbillivirus, Mumps virus, Rubella virus, Varicella-zoster virus
|
negative-sense, single-stranded RNA
|
Live-attenuated
|
Approved
|
GlaxoSmithKline
|
2019
|
NA
|
11 months - 22 months
|
2 doses 42 days apart
|
Subcutaneous
|
NA
|
Vaccinia Virus
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NCT00226499
|
https://www.fda.gov/vaccines-blood-biologics/priorix
|
https://clinicaltrials.gov/ct2/show/NCT00226499
|
|
10135
|
Varivax
|
Chickenpox
|
Exanthous
|
Varicella-zoster virus
|
double stranded DNA
|
Live-attenuated
|
Approved
|
Merck & Co. Inc.
|
2007
|
USA
|
1 - 12 years
|
2 doses (0.5 ml each) separated by at least 3 months.# First dose: age 12 through 15 months, Second dose: age 4 through 6 years
|
Subcutaneous
|
NA
|
Oka/Merck strain of live-attenuated varicella virus
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NCT00822237
|
https://www.cdc.gov/vaccines/vpd/varicella/index.html
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/varivax
|
|
10136
|
Varivax
|
Chickenpox
|
Exanthous
|
Varicella-zoster virus
|
double stranded DNA
|
Live-attenuated
|
Approved
|
Merck & Co. Inc.
|
2007
|
USA
|
12 - 23 months
|
2 doses 4 weeks apart
|
Subcutaneous
|
NA
|
Oka/Merck strain of live-attenuated varicella virus
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/vaccines/vpd/varicella/index.html
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/varivax
|
|
10137
|
ProQuad
|
Measles, Mumps, Rubella, Varicella
|
Exanthous
|
Morbillivirus, Mumps virus, Rubella virus, Varicella-zoster virus
|
negative-sense, single-stranded RNA
|
Live-attenuated
|
Approved
|
Merck & Co. Inc.
|
NA
|
USA
|
1 - 12 years
|
First dose at 12 through 15 months of age and Second dose at 4 through 6 years of age
|
Subcutaneous
|
NA
|
NA
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NCT00985166
|
https://www.cdc.gov/vaccines/vpd/varicella/index.html
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/proquad
|
|
10138
|
RotaTeq (RV5)
|
Rotavirus Infection
|
Gastrointestinal
|
Rotavirus
|
double stranded RNA
|
Live-attenuated
|
Approved
|
Merck & Co. Inc.
|
NA
|
USA
|
6 months - 8 months
|
3 doses at age of 2 months, 4 months, and 6 months
|
Oral
|
NA
|
5 human-bovine reassortant rotaviruses (G1, G2, G3 G4, P[8])
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/vaccines/vpd/rotavirus/index.html
|
https://www.fda.gov/media/75718/download
|
|
10139
|
Rotarix (RV1)
|
Rotavirus Infection
|
Gastrointestinal
|
Rotavirus
|
double stranded RNA
|
Live-attenuated
|
Approved
|
GlaxoSmithKline
|
2006
|
UK
|
6 months - 8 months
|
2 doses at ages 2 months and 4 months
|
Oral
|
NA
|
Human rotavirus strain (G1P[8])
|
NA
|
US FDA, EMA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.cdc.gov/vaccines/vpd/rotavirus/index.html
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/rotarix
|
|
10140
|
Rotavac
|
Rotavirus Infection
|
Gastrointestinal
|
Rotavirus
|
double stranded RNA
|
Live-attenuated
|
Approved
|
Bharat Biotech International Limited
|
2013
|
India
|
6 months - 8 months
|
3 doses 4 weeks apart
|
Oral
|
NA
|
Rotavirus 116E strain
|
NA
|
US FDA, Government of India
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.who.int/immunization/research/meetings_workshops/11_Cassels_Rotavirus_PDVAC_2019.pdf?ua=1
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/rotavirus-vaccine-live-oral
|
|
10141
|
RotaSiil
|
Rotavirus Infection
|
Gastrointestinal
|
Rotavirus
|
double stranded RNA
|
Live-attenuated
|
Approved
|
Serum Institute of India
|
2017
|
India
|
6 months - 8 months
|
3 doses 4 weeks apart
|
Oral
|
NA
|
Human-bovine reassortant rotaviruses (G1, G2, G3, G4, G9)
|
NA
|
National Institute of Health, Government of India
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.who.int/immunization/research/meetings_workshops/11_Cassels_Rotavirus_PDVAC_2019.pdf?ua=1
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/rotarix
|
|
10142
|
BL 125296
|
Adenovirus Infection
|
Respiratory
|
Adenovirus Type 4, Type 7
|
double stranded DNA
|
Live-attenuated
|
Approved
|
Barr Pharmaceuticals Inc.
|
NA
|
USA
|
17 - 50 years
|
2 doses
|
Oral
|
NA
|
Live adenovirus
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.fda.gov/media/80211/download
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/adenovirus-type-4-and-type-7-vaccine-live-oral
|
|
10143
|
Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted
|
Influenza (flu)
|
Respiratory
|
Influenza A virus H5N1
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
ID Biomedical Corporation of Quebec
|
2013
|
USA
|
6 months and above
|
2 doses 21 days apart
|
Intramuscular
|
AS03
|
A/H5N1 influenza antigen
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.fda.gov/media/87479/download
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/influenza-h5n1-virus-monovalent-vaccine-adjuvanted
|
|
10144
|
AUDENZ
|
Influenza (flu)
|
Respiratory
|
Influenza A virus H5N1
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Seqirus
|
2020
|
USA
|
6 months and above
|
2 doses 21 days apart
|
Intramuscular
|
MF59
|
Influenza virus strain A/turkey/Turkey/1/2005-NIBRG-23
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.fda.gov/media/135020/download
|
https://www.fda.gov/vaccines-blood-biologics/audenz
|
|
10145
|
Fluvirin
|
Influenza (flu)
|
Respiratory
|
Influenza virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Approved
|
Seqirus
|
NA
|
USA
|
4 years and above
|
2 doses at least 1 month apart
|
Intramuscular
|
NA
|
Influenza subtypes A and B
|
NA
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.fda.gov/media/75156/download
|
https://www.fda.gov/vaccines-blood-biologics/vaccines/fluvirin
|